Definitive Healthcare ( NASDAQ:DH – Get Free Report ) ‘s stock had its 'buy' rating restated by analysts at Needham & Company LLC in a report released on Tuesday, Benzinga reports. They currently have a $15.00 price objective on the stock. Needham & Company LLC's target price suggests a potential upside of 36.36% from the stock's current price. Several other research analysts also recently weighed in on DH. Barclays reduced their price target on shares of Definitive Healthcare from $11.00 to $10.

https://www.dailypolitical.com/2023/08/01/needham-company-llc-reaffirms-buy-rating-for-definitive-healthcare-nasdaqdh.html

#dailypolitical